Von Hippel-Lindau

Von Hippel-Lindau Disease Market Outlook

The global Von Hippel-Lindau (VHL) disease market is poised to reach approximately USD 1.82 billion by 2035, exhibiting a robust compound annual growth rate (CAGR) of around 7.4% from 2025 to 2035. This growth is primarily driven by advancements in medical technologies, increasing awareness about VHL disease, and the rising prevalence of related tumors such as hemangioblastomas and renal cell carcinoma. Additionally, the growing demand for personalized treatment strategies and early diagnostic techniques is also contributing to the overall market expansion. Increased government funding for cancer research, coupled with the development of innovative therapies and surgical techniques, further supports the growth of this market. The expanding patient population and the push towards improved healthcare infrastructure worldwide will also play a vital role in shaping the VHL disease market over the forecast period.

Growth Factor of the Market

The growth factors driving the Von Hippel-Lindau disease market are multifaceted and stem from various medical, technological, and regulatory advancements. Firstly, the increase in genetic testing and diagnostic capabilities has made it easier to identify patients who may be predisposed to VHL-related tumors, facilitating earlier intervention and management. Secondly, innovative treatment modalities such as targeted therapies and minimally invasive surgical options are becoming more prevalent, providing patients with improved outcomes and quality of life. Furthermore, the rising incidence of VHL disease and associated malignancies, driven by genetic predisposition in affected families, is amplifying the demand for specialized treatment options. The integration of digital health solutions and telemedicine into healthcare systems is further revolutionizing patient care, allowing for timely consultations and follow-ups. Additionally, the growing investment in research and development by pharmaceutical companies to create new drug therapies and treatment regimens adds significant momentum to the market.

Key Highlights of the Market

• Significant advancements in genetic testing and diagnostic techniques are leading to earlier detection of VHL disease.
• Increasing prevalence of associated tumors such as hemangioblastomas and renal cell carcinoma is driving market growth.
• Emergence of targeted therapies and minimally invasive surgical procedures enhances patient outcomes.
• Growing awareness and education about VHL disease among healthcare professionals and patients promote timely intervention.
• Investment in research and development is fostering innovation in treatment options and therapies.

By Disease Type

Hemangioblastomas:

Hemangioblastomas are the most common tumors associated with Von Hippel-Lindau disease, and they primarily occur in the brain and spinal cord. The nature of these tumors, being highly vascular, often leads to significant neurological complications, thus increasing the urgency for treatment. The growing recognition of the correlation between genetic predisposition and the development of hemangioblastomas has heightened awareness and prompted earlier diagnosis. Treatment options typically involve surgical resection, which can be complicated by the tumor's vascularity. The increasing incidence and awareness of hemangioblastomas are expected to drive market growth, as patients seek specialized treatment and care options.

Clear Cell Renal Cell Carcinoma:

Clear Cell Renal Cell Carcinoma (ccRCC) is another prominent manifestation of Von Hippel-Lindau disease. It is characterized by aggressive tumor behavior and a poor prognosis if not identified early. The rising incidence rate of ccRCC among individuals with a VHL diagnosis has driven significant attention to this subtype. Advances in imaging techniques, including MRI and CT scans, have improved detection rates, leading to a focus on early-stage treatment options. Targeted therapies that focus on the specific genetic mutations characteristic of ccRCC are becoming more prevalent, contributing to enhanced survival rates for affected patients. This shift towards personalized medicine is anticipated to bolster the market for treatment options pertaining to clear cell renal cell carcinoma.

Pheochromocytomas:

Pheochromocytomas, although less common, are critical manifestations of VHL disease that involve the adrenal glands, leading to excessive catecholamine production and severe cardiovascular complications. The increasing focus on genetic predisposition and the hereditary nature of pheochromocytomas has resulted in heightened surveillance among patients with a family history of VHL. Management often involves surgical intervention to remove the adrenal tumor, and the growing awareness of the condition has propelled the demand for specialized surgical expertise and post-operative care. The overall cancer care infrastructure is evolving to support patients with pheochromocytomas, which in turn is expected to influence market growth positively.

Pancreatic Neuroendocrine Tumors:

Pancreatic neuroendocrine tumors (PNETs) are increasingly recognized as a significant concern in VHL patients. These tumors can lead to a range of metabolic disorders and complications, making their management particularly challenging. The rarity of PNETs within the broader context of pancreatic tumors often results in late-stage diagnosis, thus necessitating comprehensive treatment strategies. Innovations in minimally invasive surgical techniques and the development of targeted therapies are improving outcomes for patients with PNETs. The rising incidence of this tumor type in VHL patients is expected to foster growth in the market, as healthcare providers seek to enhance treatment protocols and patient care pathways.

Endolymphatic Sac Tumors:

Endolymphatic sac tumors, though rare, are significant manifestations of VHL disease that can lead to hearing impairment and balance issues. The increasing recognition of the association between VHL and these tumors has led to a more focused surveillance approach among at-risk individuals. Treatment often involves surgical intervention, but the complexity of these tumors requires specialized knowledge and techniques. The market for managing endolymphatic sac tumors is expected to expand as awareness of this condition grows among healthcare professionals and patients, leading to increased demand for specialized treatment options and follow-up care.

By Treatment Type

Surgery:

Surgery remains a cornerstone of treatment for various manifestations of Von Hippel-Lindau disease, particularly hemangioblastomas and renal cell carcinomas. Surgical intervention aims to remove tumors while preserving surrounding healthy tissue, thereby minimizing complications and improving patient outcomes. Advances in surgical techniques, such as laparoscopic and robotic-assisted surgeries, have made these procedures less invasive and more effective, leading to shorter recovery times and lower morbidity rates. The increasing volume of surgeries performed for VHL-related tumors is expected to significantly impact the market, as patients increasingly seek these effective and less invasive solutions.

Medications:

The introduction of various medications targeting VHL-related tumors is transforming the treatment landscape for affected patients. Targeted therapies, including tyrosine kinase inhibitors and mTOR inhibitors, have shown promise in managing tumors associated with VHL disease. These medications aim to inhibit specific pathways involved in tumor growth, providing patients with options that extend their life expectancy. As research continues to unravel the molecular underpinnings of VHL-related tumors, the market for medications is expected to expand, offering new avenues for treatment and improving the overall prognosis for patients.

Radiation Therapy:

Radiation therapy is often utilized as an adjunct treatment option for patients with VHL disease, particularly for those with inoperable tumors or cases where surgery poses significant risks. The application of stereotactic radiosurgery offers precise targeting of tumors while sparing surrounding healthy tissue, making it an attractive option for patients. As advancements in radiation techniques continue to emerge, their adoption in the treatment protocols for VHL-associated tumors is anticipated to grow. This is likely to enhance patient outcomes and broaden treatment options, thus impacting the market positively.

Embolization Therapy:

Embolization therapy is an innovative treatment option for certain tumors associated with Von Hippel-Lindau disease, particularly hemangioblastomas. By selectively blocking blood flow to the tumor, embolization can reduce its size and associated symptoms. This procedure is often used in conjunction with surgical resection, allowing patients to undergo less invasive surgeries and improve overall outcomes. The increasing recognition of the benefits of embolization therapy in the management of VHL-related tumors is likely to expand its utilization, contributing to the growth of the market.

Surveillance:

Surveillance is a crucial aspect of managing Von Hippel-Lindau disease, as it allows for the early detection and management of tumors before they progress. Regular imaging and follow-ups are essential components of surveillance protocols designed for patients with a known diagnosis of VHL. The rising awareness of the importance of consistent monitoring has led to increased demand for surveillance services, particularly among healthcare facilities specializing in genetic disorders and oncology. As more healthcare providers implement comprehensive surveillance programs, the market for these services is expected to grow significantly.

By User

Hospitals:

Hospitals play a pivotal role in the management and treatment of Von Hippel-Lindau disease, providing a wide range of services from diagnostics to surgical interventions. With access to advanced medical technologies and multidisciplinary teams, hospitals are equipped to deliver comprehensive care for patients dealing with VHL-associated tumors. The increasing number of hospitalizations due to complications arising from VHL disease necessitates the ongoing development of specialized hospital units and programs. This focus on enhancing hospital-based care is expected to drive the market, as more patients seek treatment options within these institutions.

Specialty Clinics:

Specialty clinics focused on oncology and genetic disorders are emerging as critical players in the management of Von Hippel-Lindau disease. These clinics often provide a more personalized approach to patient care and offer specialized services such as genetic counseling, targeted therapies, and regular surveillance. The growing demand for expert care in managing complex conditions like VHL is leading to an increase in specialty clinics dedicated to this purpose. As patients increasingly seek out these facilities for their expertise, the market for specialty clinics is expected to flourish, contributing to overall advancements in care.

Research Institutes:

Research institutes are integral to the VHL market, as they drive innovation and advancements in treatment options. Focused on understanding the genetic and molecular mechanisms of VHL disease, these institutes are developing new therapies and improving diagnostic methods. The collaboration between research institutions and clinical providers is facilitating the transition of discoveries from the laboratory to practical applications in patient care. As funding for cancer research continues to grow, the role of research institutes in shaping the future of VHL treatment is expected to expand, ultimately influencing the market landscape.

By Diagnostic Techniques

Genetic Testing:

Genetic testing is a fundamental component in the diagnosis and management of Von Hippel-Lindau disease. It enables early identification of individuals at risk of developing VHL-related tumors based on familial genetic mutations. This proactive approach is crucial as it facilitates timely interventions, potentially improving outcomes. As awareness of the importance of genetic testing among healthcare providers and patients increases, the market for genetic testing services is expected to grow significantly. Moreover, advancements in sequencing technologies are making genetic testing more accessible and affordable, further propelling its adoption in clinical settings.

Imaging Tests:

Imaging tests, including MRI and CT scans, are vital in the monitoring and diagnosis of VHL disease. These non-invasive diagnostic tools allow for the visualization of tumors in various organs and aid in assessing their size, location, and potential complications. The integration of advanced imaging techniques is enhancing the accuracy and timeliness of diagnoses, which is paramount in managing VHL-related tumors. The increasing emphasis on regular imaging as part of surveillance programs is expected to drive the market for imaging tests, as patients seek comprehensive care pathways to monitor their condition effectively.

Blood and Urine Tests:

Blood and urine tests are essential diagnostic tools used to evaluate tumor markers associated with Von Hippel-Lindau disease. These tests help in the early detection of tumors and in monitoring treatment responses. The growing emphasis on minimally invasive diagnostic techniques is contributing to increased utilization of blood and urine tests, as they provide valuable information without the need for more invasive procedures. As research continues to identify new biomarkers linked to VHL, the market for blood and urine testing services is expected to expand, offering patients better management options.

Biopsy:

Biopsy remains a critical technique for confirming the presence of tumors associated with Von Hippel-Lindau disease. By obtaining tissue samples for histopathological examination, healthcare providers can accurately diagnose the type and extent of tumors, which is crucial for determining the appropriate treatment plan. While advancements in imaging have enabled many tumors to be diagnosed non-invasively, biopsy still plays an important role, particularly in cases where imaging findings are inconclusive. The ongoing focus on improving biopsy techniques and reducing associated risks is expected to enhance their utilization in the management of VHL disease, thereby positively impacting the market.

By Region

North America is expected to dominate the Von Hippel-Lindau disease market, accounting for approximately 40% of the global market share by 2035. Factors such as advanced healthcare infrastructure, a high prevalence of genetic testing, and a strong focus on research and development contribute to this region's dominance. The presence of several key players in the pharmaceutical and biotechnology sectors further strengthens the market landscape. Moreover, initiatives aimed at increasing awareness and improving access to VHL-related healthcare services are anticipated to bolster growth in this region. The CAGR for North America is projected to be around 8% during the forecast period, highlighting significant opportunities for market expansion.

Europe follows closely, holding about 30% of the global market share. The region benefits from progressive healthcare policies and an increasing focus on genetic counseling and prevention strategies for hereditary diseases like VHL. The rising demand for advanced diagnostic techniques and treatment options, alongside supportive healthcare frameworks, is expected to drive growth in the European market. The introduction of specialized clinics and centers of excellence for VHL also enhances patient care and contributes to market growth. Other regions such as Asia Pacific, Latin America, and the Middle East & Africa are gradually emerging, with a combined market share of approximately 30%, reflecting growing awareness and access to healthcare services.

Opportunities

The Von Hippel-Lindau disease market presents numerous opportunities, particularly through advancements in genetic research and personalized medicine. As genetic testing becomes more mainstream, the ability to identify at-risk individuals earlier can lead to timely interventions that can significantly alter patient outcomes. The continued evolution of targeted therapies offers the potential for more effective treatments tailored to individual genetic profiles, which is a key focus of the pharmaceutical industry. Moreover, the growing emphasis on early detection and preventive care signifies an opportunity for healthcare providers to implement comprehensive screening programs, thereby improving management strategies for at-risk populations. This proactive approach not only benefits patients but also supports healthcare systems by reducing the burden of advanced disease treatment.

Furthermore, collaboration between academic institutions, research organizations, and pharmaceutical companies can accelerate the pace of innovation in the VHL disease market. The establishment of partnerships aimed at conducting clinical trials for novel therapeutic agents can provide insights into more effective treatment options. Additionally, increasing government and private investments in cancer research are creating a favorable environment for the development of new therapies and diagnostic tools. This influx of funding and resources is likely to enhance the market landscape, paving the way for improved patient care and outcomes in the long run. The global focus on rare genetic disorders also provides a platform for greater awareness and advocacy, further driving interest in VHL disease research and treatment.

Threats

Despite the promising opportunities, the Von Hippel-Lindau disease market is not without its threats. One of the primary challenges lies in the complexities associated with the diagnosis and management of VHL disease. The rarity of the condition can lead to delays in diagnosis, which may negatively impact treatment outcomes and patient survival rates. Additionally, the variability in tumor manifestations complicates standardization in treatment protocols, potentially leading to disparities in care. Furthermore, the high costs associated with advanced diagnostic techniques and innovative treatments may limit access for patients, particularly in low-resource settings. This economic barrier can hinder the overall market growth and impact patient well-being.

Moreover, the risk of regulatory hurdles presents another challenge to the market. The approval process for new treatments, particularly in the realm of genetic therapies, can be lengthy and complex, which may delay the introduction of potentially life-saving innovations. This procedural lag can be particularly detrimental in a rapidly evolving field such as oncology. Lastly, the ongoing COVID-19 pandemic has diverted attention and resources away from routine cancer care and may discourage patients from seeking timely treatment, further complicating the landscape for VHL disease management. These threats underscore the need for a concerted effort to address challenges within the market to ensure patients receive the necessary care without undue delays.

Competitor Outlook

• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• AstraZeneca plc
• Genentech, Inc. (Roche)
• Amgen Inc.
• Incyte Corporation
• Exelixis, Inc.
• GSK plc (GlaxoSmithKline)
• Blueprint Medicines Corporation
• Takeda Pharmaceutical Company Limited
• Vertex Pharmaceuticals Incorporated
• Seattle Genetics, Inc.
• Anderson Cancer Center

The competitive landscape of the Von Hippel-Lindau disease market is characterized by the presence of numerous pharmaceutical companies, biotechnology firms, and research institutions focused on the development of innovative therapies and diagnostic techniques. Major players like Novartis AG and Merck & Co., Inc. are heavily investing in research to identify novel treatments that address the complexities of VHL disease. These companies are leveraging their extensive resources and expertise to enhance patient outcomes through targeted therapies and personalized medicine. Additionally, collaboration between these industry giants and academic institutions is fostering advancements in genetic research, leading to a better understanding of the disease mechanisms and potential therapeutic targets.

Companies like Bristol-Myers Squibb and Pfizer Inc. are also playing a significant role in the development of cancer treatments, particularly for tumors associated with VHL disease. Their commitment to research and development is driving the introduction of new therapies that aim to improve survival rates for patients with VHL-related tumors. Furthermore, the entry of smaller firms such as Blueprint Medicines Corporation and Exelixis, Inc. showcases the growing interest in niche therapeutic areas within oncology, which can open new avenues for treatment options and management strategies. As competition intensifies, these companies are likely to focus on differentiation through innovative solutions and patient-centric approaches, enhancing the market landscape.

Furthermore, leading research institutions like the Anderson Cancer Center are pivotal in conducting clinical trials and advancing the understanding of VHL disease. Their efforts in investigating the efficacy of new therapies contribute significantly to shaping the treatment paradigms for VHL patients. The collaboration between industry and research entities fosters a dynamic environment where cutting-edge solutions to complex medical challenges can emerge. As the landscape continues to evolve, the emphasis on collaborative approaches, coupled with the aspiration for innovation, will shape the competitive outlook of the Von Hippel-Lindau disease market in the coming years.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Exelixis, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AstraZeneca plc
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Merck & Co., Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Incyte Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 erson Cancer Center
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Seattle Genetics, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Genentech, Inc. (Roche)
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GSK plc (GlaxoSmithKline)
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bristol-Myers Squibb Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Blueprint Medicines Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Vertex Pharmaceuticals Incorporated
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Von Hippel-Lindau Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Specialty Clinics
    • 6.1.3 Research Institutes
  • 6.2 Von Hippel-Lindau Market, By Disease Type
    • 6.2.1 Hemangioblastomas
    • 6.2.2 Clear Cell Renal Cell Carcinoma
    • 6.2.3 Pheochromocytomas
    • 6.2.4 Pancreatic Neuroendocrine Tumors
    • 6.2.5 Endolymphatic Sac Tumors
  • 6.3 Von Hippel-Lindau Market, By Treatment Type
    • 6.3.1 Surgery
    • 6.3.2 Medications
    • 6.3.3 Radiation Therapy
    • 6.3.4 Embolization Therapy
    • 6.3.5 Surveillance
  • 6.4 Von Hippel-Lindau Market, By Diagnostic Techniques
    • 6.4.1 Genetic Testing
    • 6.4.2 Imaging Tests
    • 6.4.3 Blood and Urine Tests
    • 6.4.4 Biopsy

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Von Hippel-Lindau Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Von Hippel-Lindau market is categorized based on

By Disease Type

• Hemangioblastomas
• Clear Cell Renal Cell Carcinoma
• Pheochromocytomas
• Pancreatic Neuroendocrine Tumors
• Endolymphatic Sac Tumors

By Treatment Type

• Surgery
• Medications
• Radiation Therapy
• Embolization Therapy
• Surveillance

By User

• Hospitals
• Specialty Clinics
• Research Institutes

By Diagnostic Techniques

• Genetic Testing
• Imaging Tests
• Blood and Urine Tests
• Biopsy

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• AstraZeneca plc
• Genentech, Inc. (Roche)
• Amgen Inc.
• Incyte Corporation
• Exelixis, Inc.
• GSK plc (GlaxoSmithKline)
• Blueprint Medicines Corporation
• Takeda Pharmaceutical Company Limited
• Vertex Pharmaceuticals Incorporated
• Seattle Genetics, Inc.
• erson Cancer Center